| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.02 | 0.7 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.009 | 0.9 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | leptomycin B | CTRPv2 | pan-cancer | AAC | -0.22 | 4e-11 |
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | -0.3 | 4e-10 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | -0.29 | 2e-09 |
| mRNA | carboplatin:UNC0638 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-07 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | -0.17 | 4e-07 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.26 | 1e-06 |